Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Current Leases: 2019-2024

Historic Current Leases for Ptc Therapeutics (PTCT) over the last 6 years, with Dec 2024 value amounting to $10.4 million.

  • Ptc Therapeutics' Current Leases fell 16.32% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 16.32%. This contributed to the annual value of $10.4 million for FY2024, which is 20.30% down from last year.
  • Ptc Therapeutics' Current Leases amounted to $10.4 million in FY2024, which was down 20.30% from $13.0 million recorded in FY2023.
  • Over the past 5 years, Ptc Therapeutics' Current Leases peaked at $13.0 million during FY2023, and registered a low of $7.3 million during FY2021.
  • Over the past 3 years, Ptc Therapeutics' median Current Leases value was $10.4 million (recorded in 2024), while the average stood at $10.9 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Current Leases surged by 44.87% in 2020, and later dropped by 20.30% in 2024.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Current Leases stood at $7.5 million in 2020, then decreased by 2.57% to $7.3 million in 2021, then grew by 28.83% to $9.4 million in 2022, then spiked by 38.76% to $13.0 million in 2023, then declined by 20.30% to $10.4 million in 2024.